BeiGene (HKG:6160, SHA:688235) recorded a net income of $1.3 million in the first quarter, compared with a net loss of $251.2 million in the year-ago period, a Wednesday Hong Kong bourse filing said.
The company did not make any earnings per share in the three months, while it had incurred a loss per share of $0.19 in the corresponding period of the last year.
Revenue for the pharmaceutical company rose 49% to $1.12 billion in the quarter from $751.7 million a year prior, driven primarily by higher product sales under the BRUKINSA brand in the US and Europe.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。